• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PI-RADS 版本 2:用于确定外周带前列腺癌动态对比增强 MRI 阳性的最佳时间范围。

PI-RADS version 2: optimal time range for determining positivity of dynamic contrast-enhanced MRI in peripheral zone prostate cancer.

机构信息

Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea.

Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.

出版信息

Clin Radiol. 2019 Nov;74(11):895.e27-895.e34. doi: 10.1016/j.crad.2019.06.014. Epub 2019 Jul 18.

DOI:10.1016/j.crad.2019.06.014
PMID:31327469
Abstract

AIM

To analyse the optimal time cut-off for determining positivity of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) in peripheral zone (PZ) prostate cancer (PCa).

MATERIALS AND METHODS

A consecutive series of 89 patients with PZ PCa who had undergone diffusion-weighted imaging (DWI) and subtraction DCE MRI were included. An experienced reader visually analysed the earliest time after contrast medium injection to visualise the best contrast between an index tumour and normal PZ on DCE MRI (i.e., best contrast time). The best contrast time cut-off for clinically significant cancer (csPCa) according to Epstein criteria or International Society of Urological Pathology (ISUP) grade ≥2 was analysed by an experienced reader, and applied to a less-experienced reader. For the index lesion of DWI category 3, the added value of DCE MRI (increased true positive and negative rates of PI-RADSv2 for csPCa) was evaluated using the cut-off time.

RESULTS

The best contrast time cut-off for csPCa was ≤72 seconds for Epstein criteria and ≤56 seconds for ISUP grade ≥2 by an experienced reader. The weighted kappa to determine positivity of DCE MRI was 0.622 for ≤72 seconds and 0.527 for ≤56 seconds between the two readers. The added value of DCE MRI was 55-75% by an experienced reader and 39.1-69.6% by a less-experienced reader.

CONCLUSION

For interpreting PI-RADSv2, imaging findings within 60-72 seconds following contrast media injection seem to reliably determine positivity of DCE MRI in PZ, and have added value for detecting csPCa.

摘要

目的

分析确定周边区(PZ)前列腺癌(PCa)动态对比增强(DCE)磁共振成像(MRI)阳性的最佳时间截止值。

材料和方法

纳入了 89 例连续接受扩散加权成像(DWI)和减影 DCE MRI 检查的 PZ PCa 患者。一位有经验的读者对最早时间进行了视觉分析,即对比剂注射后能在 DCE MRI 上观察到指数肿瘤与正常 PZ 之间的最佳对比(即最佳对比时间)。根据 Epstein 标准或国际泌尿病理学会(ISUP)分级≥2,有经验的读者分析了最佳对比时间截止值对临床显著癌(csPCa)的影响,并将其应用于经验较少的读者。对于 DWI 类别 3 的指数病变,使用截止时间评估 DCE MRI 的附加价值(增加 PI-RADSv2 对 csPCa 的真阳性和真阴性率)。

结果

有经验的读者确定 csPCa 的最佳对比时间截止值为 Epstein 标准≤72 秒,ISUP 分级≥2≤56 秒。两位读者之间 DCE MRI 阳性判断的加权 Kappa 值为≤72 秒时为 0.622,≤56 秒时为 0.527。DCE MRI 的附加价值为经验丰富的读者 55-75%,经验较少的读者 39.1-69.6%。

结论

对于解读 PI-RADSv2,注射对比剂后 60-72 秒内的影像学表现似乎可以可靠地确定 PZ 中 DCE MRI 的阳性,并且对检测 csPCa 具有附加价值。

相似文献

1
PI-RADS version 2: optimal time range for determining positivity of dynamic contrast-enhanced MRI in peripheral zone prostate cancer.PI-RADS 版本 2:用于确定外周带前列腺癌动态对比增强 MRI 阳性的最佳时间范围。
Clin Radiol. 2019 Nov;74(11):895.e27-895.e34. doi: 10.1016/j.crad.2019.06.014. Epub 2019 Jul 18.
2
Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.探讨 DCE-MRI 相对于 T2 和 DWI 在经根治性前列腺切除术定义的有临床意义的外周带前列腺病变的 PI-RADS v2 评估中的准确作用。
Abdom Radiol (NY). 2019 Apr;44(4):1520-1527. doi: 10.1007/s00261-018-1807-6.
3
Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.前列腺影像报告和数据系统版本 1 和 2 用于检测外周区 Gleason 评分 3+4=7 癌的比较。
AJR Am J Roentgenol. 2017 Dec;209(6):W365-W373. doi: 10.2214/AJR.17.17964. Epub 2017 Oct 5.
4
Dynamic Contrast-Enhanced MRI-Upgraded Prostate Imaging Reporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm.动态对比增强磁共振成像报告和数据系统第 2 版前列腺外周带观察分类 3 级,以 15mm 为大小阈值分层。
AJR Am J Roentgenol. 2019 Oct;213(4):836-843. doi: 10.2214/AJR.18.21005. Epub 2019 May 23.
5
Diagnostic Performance of Mass Enhancement on Dynamic Contrast-Enhanced MRI for Predicting Clinically Significant Peripheral Zone Prostate Cancer.基于动态对比增强磁共振成像的质量增强对预测临床显著外周带前列腺癌的诊断性能。
AJR Am J Roentgenol. 2020 Apr;214(4):792-799. doi: 10.2214/AJR.19.22072. Epub 2020 Feb 18.
6
[Effects of dynamic contrast enhancement on diffusion weighted imaging score of 3 in prostate imaging reporting and data system version 2 of peripheral zone].[动态对比增强对前列腺影像报告和数据系统第2版外周带扩散加权成像3分的影响]
Zhonghua Yi Xue Za Zhi. 2020 Apr 7;100(13):1002-1006. doi: 10.3760/cma.j.cn112137-20190816-01820.
7
Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.动态对比增强(DCE)磁共振成像在PI-RADS-4级患者外周病变中的价值
Rofo. 2020 May;192(5):441-447. doi: 10.1055/a-1020-4026. Epub 2019 Oct 17.
8
Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.动态对比增强磁共振成像和扩散加权磁共振成像对前列腺影像报告和数据系统(PI-RADS)检测临床显著性前列腺癌的贡献
Radiology. 2023 Jan;306(1):186-199. doi: 10.1148/radiol.212692. Epub 2022 Aug 16.
9
Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.用于原发性前列腺癌评估的合成磁共振成像:通过弛豫测量增强的非对比增强双参数方法的诊断潜力
Eur J Radiol Open. 2022 Feb 15;9:100403. doi: 10.1016/j.ejro.2022.100403. eCollection 2022.
10
Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?动态对比增强 MRI 升级为 PI-RADS 4 的 PI-RADS 3 级肿瘤中癌症的检出率较低:是否是时候重新考虑评分分类了?
Eur Radiol. 2023 Aug;33(8):5828-5839. doi: 10.1007/s00330-023-09605-0. Epub 2023 Apr 13.

引用本文的文献

1
Abbreviated MR Protocols in Prostate MRI.前列腺MRI的简化磁共振成像协议
Life (Basel). 2022 Apr 7;12(4):552. doi: 10.3390/life12040552.
2
The role of MRI in prostate cancer: current and future directions.MRI 在前列腺癌中的作用:现状与未来方向。
MAGMA. 2022 Aug;35(4):503-521. doi: 10.1007/s10334-022-01006-6. Epub 2022 Mar 16.
3
Prostate Imaging-Reporting and Data System: Comparison of the Diagnostic Performance between Version 2.0 and 2.1 for Prostatic Peripheral Zone.前列腺影像报告和数据系统:2.0 版和 2.1 版在前列腺外周区诊断性能的比较。
Korean J Radiol. 2021 Jul;22(7):1100-1109. doi: 10.3348/kjr.2020.0837. Epub 2021 Apr 9.